5,638 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Mosaic Financial Group LLC

Mosaic Financial Group LLC acquired a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 5,638 shares of the company's stock, valued at approximately $369,000.

Several other institutional investors have also modified their holdings of the company. Albion Financial Group UT increased its position in shares of AstraZeneca by 68.9% in the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after acquiring an additional 248 shares in the last quarter. Groupama Asset Managment increased its stake in shares of AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company's stock worth $42,000 after acquiring an additional 101,225 shares during the last quarter. Versant Capital Management Inc raised its holdings in shares of AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company's stock worth $48,000 after acquiring an additional 707 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of AstraZeneca during the 4th quarter valued at about $55,000. Finally, Golden State Wealth Management LLC bought a new position in AstraZeneca during the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Stock Performance

AstraZeneca stock traded down $5.46 on Friday, reaching $68.46. 9,210,887 shares of the stock were exchanged, compared to its average volume of 5,143,446. The stock has a market cap of $212.31 billion, a PE ratio of 30.29, a PEG ratio of 1.42 and a beta of 0.49. The firm has a fifty day moving average price of $73.96 and a two-hundred day moving average price of $71.43. AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.

Remove Ads

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. Sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, March 24th. Stockholders of record on Friday, February 21st were issued a dividend of $1.03 per share. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date of this dividend was Friday, February 21st. This represents a dividend yield of 2%. AstraZeneca's payout ratio is presently 91.15%.

Analyst Upgrades and Downgrades

Several analysts have commented on AZN shares. Morgan Stanley began coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company. UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.